BridgeBio Pharma, Inc. - 8-K Filing
FDA accepted BridgeBio's NDA for encaleret for ADH1 with a PDUFA date of May 8, 2027 (Items: 8.01 Other Events On July 22, 2026, BridgeBio Pharma, Inc, 9.01 Financial Statements and Exhibits)
Tickers: $BBIO
More Regulatory news
- Carter Bankshares, Inc. - 8-K Filing
- Marvell Technology, Inc. - 8-K Filing
- VISHAY INTERTECHNOLOGY INC - 8-K Filing
- LATTICE SEMICONDUCTOR CORP - 4 Filing
- CENTRUS ENERGY CORP - 8-K Filing
- SAGA COMMUNICATIONS INC - 8-K Filing
- NextBoat Inc. - 8-K Filing
- CIVISTA BANCSHARES, INC. - 8-K Filing
- RF Acquisition Corp II - 10-Q Filing
- ORASURE TECHNOLOGIES INC - 10-Q Filing